A. Paci, B. Bleton, H. Mazeau, D. Ussel, and A. , Médecine personnalisée et cancer: organiser et financer l'accès à l'innovation. IGR press, 2013.

E. Bravo and R. Tagle, Pheochromocytoma: State-of-the-Art and Future Prospects, Endocrine Reviews, vol.24, issue.4, pp.539-53, 2003.
DOI : 10.1210/er.2002-0013

R. Lloyd, A. Tischler, and N. Kimura, Adrenal tumours : Introduction. RA DeLellis PU Heitz C Eng WHO Classifi Cation Tumours-Pathol Genet-Tumours Endocr Organs, 2004.

N. Burnichon, J. Favier, and A. Gimenez-roqueplo, Phéochromocytomes et Paragangliomes: aspects récents. Actual Néphrologiques Jean Hambg Hôp Necker, 2011.

A. Gimenez-roqueplo, Phéochromocytome-paragangliome héréditaire. Orphanet, 2011.

J. Hadoux, J. Favier, J. Scoazec, S. Leboulleux, A. Ghuzlan et al., mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma, International Journal of Cancer, vol.118, issue.Suppl 2, pp.2711-2731, 2014.
DOI : 10.1002/ijc.28913

H. Autorité and D. Santé, Guide Affection de longue durée -Cancer du rein de l'adulte [Internet], 2010.

C. Ricketts, E. Woodward, P. Killick, M. Morris, D. Astuti et al., Germline SDHB Mutations and Familial Renal Cell Carcinoma, JNCI Journal of the National Cancer Institute, vol.100, issue.17, pp.1260-1262, 2008.
DOI : 10.1093/jnci/djn254

H. Krebs and L. Eggleston, The oxidation of pyruvate in pigeon breast muscle, Biochemical Journal, vol.34, issue.3, pp.442-59, 1940.
DOI : 10.1042/bj0340442

I. Tomlinson, N. Alam, A. Rowan, E. Barclay, E. Jaeger et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, vol.30, issue.4, pp.406-416, 2002.
DOI : 10.1038/ng849

O. Warburg, The reaction of ascites tumor cells to oxygen under high pressure], Arch Für Geschwulstforsch, vol.6, issue.1, pp.7-11, 1953.

E. Gottlieb and I. Tomlinson, Mitochondrial tumour suppressors: a genetic and biochemical update, Nature Reviews Cancer, vol.284, issue.11, pp.857-66, 2005.
DOI : 10.1074/jbc.M204958200

A. Kelly, S. Breitkopf, M. Yuan, J. Goldsmith, D. Spentzos et al., Metabolomic Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Tissue Using Targeted LC/MS/MS: Application in Sarcoma, PLoS ONE, vol.6, issue.10, p.25357, 2011.
DOI : 10.1371/journal.pone.0025357.s005

Y. Liu, Z. Hong, G. Tan, X. Dong, G. Yang et al., NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis, International Journal of Cancer, vol.54, issue.3, 2014.
DOI : 10.1002/ijc.28706

S. Richter, M. Peitzsch, E. Rapizzi, J. Lenders, N. Qin et al., Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.10, pp.3903-3914, 2014.
DOI : 10.1210/jc.2014-2151

B. Tan, Z. Lu, S. Dong, G. Zhao, and M. Kuo, Derivatization of the tricarboxylic acid intermediates with O-benzylhydroxylamine for liquid chromatography???tandem mass spectrometry detection, Analytical Biochemistry, vol.465, pp.134-181, 2014.
DOI : 10.1016/j.ab.2014.07.027

E. Struys, Measurement of Urinary D- and L-2-Hydroxyglutarate Enantiomers by Stable-Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry after Derivatization with Diacetyl-L-Tartaric Anhydride, Clinical Chemistry, vol.50, issue.8, pp.1391-1396, 2004.
DOI : 10.1373/clinchem.2004.033399

C. Dinardo, K. Propert, A. Loren, E. Paietta, Z. Sun et al., Serum 2- hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood, Jun, vol.13121, issue.24, pp.4917-4941, 2013.

V. Poinsignon, L. Mercier, K. Nakabayashi, A. Lalli, M. David et al., LC-MS/MS method after derivation for the determination of L and D isomers of 2- hydroxyglutaric acid in biological fluids, suitable for clinical applications in IDH mutated cancers, À Par J Chromatogr B, 2015.

I. Guideline, Validation of analytical procedures: Text and Methodology, Q2 R1 [Internet], 2005.

E. Guideline, Guideline on bioanalytical method validation Available from, 2011.

T. Barri and L. Dragsted, UPLC-ESI-QTOF/MS and multivariate data analysis for blood plasma and serum metabolomics: Effect of experimental artefacts and anticoagulant, Analytica Chimica Acta, vol.768, pp.118-146
DOI : 10.1016/j.aca.2013.01.015

W. Guder, S. Narayanan, H. Wisser, and B. Zawta, Samples:From the Patient to the Laboratory: The impact of preanalytical variables on the quality of laboratory results, 2008.

B. Baysal, Hereditary paraganglioma targets diverse paraganglia, Journal of Medical Genetics, vol.39, issue.9, pp.617-639, 2002.
DOI : 10.1136/jmg.39.9.617

P. Plouin, J. Duclos, F. Soppelsa, G. Boublil, and G. Chatellier, Factors Associated with Perioperative Morbidity and Mortality in Patients with Pheochromocytoma: Analysis of 165 Operations at a Single Center, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.4, pp.1480-1486, 2001.
DOI : 10.1210/jc.86.4.1480

N. Burnichon, V. Rohmer, L. Amar, P. Herman, S. Leboulleux et al., The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.8, pp.2817-2844, 2009.
DOI : 10.1210/jc.2008-2504

L. Amar, E. Baudin, N. Burnichon, S. Peyrard, S. Silvera et al., Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.10, 2007.
DOI : 10.1210/jc.2007-0709

J. Favier and A. Gimenez-roqueplo, Pheochromocytomas: The (pseudo)-hypoxia hypothesis, Best Practice & Research Clinical Endocrinology & Metabolism, vol.24, issue.6, pp.957-68, 2010.
DOI : 10.1016/j.beem.2010.10.004

N. Burnichon, C. Lepoutre-lussey, J. Laffaire, N. Gadessaud, V. Molinié et al., A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma, European Journal of Endocrinology, vol.164, issue.1
DOI : 10.1530/EJE-10-0758

G. Monges, S. Bisot-locard, J. Blay, A. Bouvier, M. Urbieta et al., The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists, Bull Cancer, vol.97, issue.3, pp.16-22, 2010.

H. Loiseau, A. Huchet, and I. Baldi, ??pid??miologie des tumeurs c??r??brales primitives, Revue Neurologique, vol.165, issue.8-9, pp.83-89, 2010.
DOI : 10.1016/j.neurol.2009.04.002

M. Miettinen and J. Lasota, Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) ??? A review, The International Journal of Biochemistry & Cell Biology, vol.53, pp.514-523
DOI : 10.1016/j.biocel.2014.05.033

A. J. Gill, Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas, The American Journal of Surgical Pathology, vol.38, issue.4, pp.560-566, 2014.
DOI : 10.1097/PAS.0000000000000149